Neurocrine Biosciences Reports Strong Q2 2026 Performance and Strategic Growth
Neurocrine Biosciences reported strong performance for Q2 2026, driven by record new patient additions to INGREZZA and the successful launch of CRENESSITY. The company raised its full-year guidance midpoint, reflecting a projected 13% year-over-year revenue growth. Management highlighted the transformation from a single-product entity into a diversified commercial leader with three first-in-class medicines generating approximately $4 billion in annual sales. The acquisition of Soleno and VYKAT XR was described as strategically beneficial, immediately boosting non-GAAP earnings while expanding Neurocrine’s presence in rare diseases and endocrinology. The company also emphasized its leadership position within the VMAT2 inhibitor category despite competitive pressures. Looking ahead, multiple Phase 3 clinical trials are expected to deliver data readouts for osavampator and dereclidine by mid-2027. Financially, Neurocrine financed the $2.9 billion Soleno acquisition with cash reserves, leaving it with $500 million in liquidity at quarter-end. The company acknowledged integration challenges related to VYKAT XR but expressed confidence that sequential growth would resume after discontinuation rates stabilize.
Tickers: $NBIX
Topics: Earnings Performance Pharmaceuticals Pipeline Development